ASLAN Pharmaceuticals (ASLN) Stock Forecast, Price Target & Predictions
ASLN Stock Forecast
ASLAN Pharmaceuticals stock forecast is as follows:
ASLAN Pharmaceuticals Financial Forecast
ASLAN Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $3.00M |
| High Forecast | - | - | - | - | - | - | - | - | $3.00M |
| Low Forecast | - | - | - | - | - | - | - | - | $3.00M |
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
ASLAN Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ASLN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ASLAN Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $600.00K |
| High Forecast | - | - | - | - | - | - | - | - | $600.00K |
| Low Forecast | - | - | - | - | - | - | - | - | $600.00K |
| Surprise % | - | - | - | - | - | - | - | - | - |
undefined analysts predict ASLN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ASLAN Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
ASLAN Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| Net Income | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-94.10M | $-89.62M | $-86.63M | $-82.15M | $-1.49M | $-2.99M | $-2.99M | $-47.80M | $-176.75M |
| High Forecast | $-94.10M | $-89.62M | $-86.63M | $-82.15M | $-1.49M | $-2.99M | $-2.83M | $-47.80M | $-176.75M |
| Low Forecast | $-94.10M | $-89.62M | $-86.63M | $-82.15M | $-1.49M | $-2.99M | $-3.14M | $-47.80M | $-176.75M |
| Surprise % | - | - | - | - | - | - | - | - | - |
ASLAN Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ASLN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ASLAN Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| SG&A | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | $4.15M |
| High Forecast | - | - | - | - | - | - | - | - | $4.15M |
| Low Forecast | - | - | - | - | - | - | - | - | $4.15M |
| Surprise % | - | - | - | - | - | - | - | - | - |
ASLAN Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ASLN last annual SG&A of $NaN (undefined).
ASLAN Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | - |
| EPS | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-5.04 | $-4.80 | $-4.64 | $-4.40 | $-0.08 | $-0.16 | $-0.16 | $-2.56 | $-9.47 |
| High Forecast | $-5.04 | $-4.80 | $-4.64 | $-4.40 | $-0.08 | $-0.16 | $-0.15 | $-2.56 | $-9.47 |
| Low Forecast | $-5.04 | $-4.80 | $-4.64 | $-4.40 | $-0.08 | $-0.16 | $-0.17 | $-2.56 | $-9.47 |
| Surprise % | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, ASLAN Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ASLN previous annual EPS of $NaN (undefined).
ASLAN Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.24 | $36.00 | 1507.14% | Buy |
| ASLN | ASLAN Pharmaceuticals | $0.60 | $5.50 | 816.67% | - |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| NAMS | NewAmsterdam Pharma Company | $15.96 | $36.00 | 125.56% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| AGIO | Agios Pharmaceuticals | $46.69 | $47.50 | 1.73% | Buy |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
ASLN Forecast FAQ
What are ASLAN Pharmaceuticals's analysts' financial forecasts?
ASLAN Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-55.265M (high $-55.107M, low $-55.422M), average SG&A $0 (high $0, low $0), and average EPS is $-2.96 (high $-2.952, low $-2.968). ASLN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-352M (high $-352M, low $-352M), average SG&A $0 (high $0, low $0), and average EPS is $-18.88 (high $-18.88, low $-18.88).